Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONSET-1 Safety Follow-up
NCT03920215Phase 3Completed
- Sponsor
- Oyster Point Pharma
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varenicline + nicotine patch in dry eye disease (DED) (4 arms), sponsored by Oyster Point Pharma. Primary endpoints: Number of Participants With the Left Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations, Number of Participants With the Right Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations and 2 more. Started Aug 2018; status: completed.
02
Drugs
varenicline + nicotine patch
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03920215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920215.